Sponsors should be aware of the significant implications the Addendum is likely to have on clinical trial planning, conduct, statistical analysis, and interpretation.
Ülker Aydemir
Advertisement
Articles by Ülker Aydemir
Advertisement
Latest Updated Articles
- Estimands and Implications for Sponsors as ICH E9 (R1) Addendum Progresses
Published: December 13th 2017 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Evolution of Global Trial Strategies in Today's Complex Healthcare Landscape
2
The Business Case for DEI in Pharmaceutical Innovation: Why Organizational Commitment Matters for Inclusive Clinical Trials
3
Centering Site Experience to Accelerate Study Activation
4
ACT Brief: Life Sciences Hold the Line on DEI, Startup Timelines Stretch Further, and Regulators Align on AI Governance
5